Adding belzutifan to standard adjuvant pembrolizumab cut the risk for recurrence or death in patients with resected clear cell renal cell carcinoma.
Merck presents positive results from phase 3 LITESPARK-022 trial of Keytruda plus Welireg in certain patients with earlier-stage RCC at 2026 ASCO cancers symposium: Rahway, New Je ...
The combination of belzutifan plus lenvatinib significantly improved outcomes for patients with clear cell renal cell ...
A large national study in Denmark following nearly 1,900 patients over almost a decade has found that a minimally invasive ...
The 2026 GU ASCO annual meeting featured a renal cell carcinoma session and a discussant presentation by Dr. Beckermann, ...
Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.
The combination of fruquintinib and serplulimab has shown antitumor activity in treatment-naive advanced non-clear cell renal cell carcinoma.
At 24 months overall survival was 62.8% with Welireg plus Lenvima versus 55.4% with Cabometyx. Median overall survival was 34 ...
Patients with advanced clear cell RCC whose disease progressed after 1-3 prior systemic therapies (including an anti–PD- [L]1 therapy) were randomly assigned 1:1 to belzutifan 200 mg or 120 mg daily: ...
SAN FRANCISCO -- The adjuvant combination of pembrolizumab (Keytruda) and belzutifan (Welireg) significantly improved disease ...
SAN FRANCISCO -- Dual antiangiogenic therapy for previously treated kidney cancer significantly improved progression-free ...
The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results